xmab13676
mAbexperimentalMulti-specific
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2016 (NCT02924402)
Timeline
Indications
Mechanism of action
CD3E
- B-lymphocyte antigen CD20BINDING AGENT
CD20
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298130 ↗
Also known as
- xmab13676
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07284797 | Phase 1 | Feb 28, 2026 | Xencor |
| NCT07230353 | Phase 1 | Oct 21, 2025 | Xencor |
| NCT05328102 | Phase 2 | Jun 30, 2022 | Xencor |
| NCT02924402 | Phase 1 | Oct 1, 2016 | Chiltern International, Xencor |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Xencor | For profit | 4 | 4 | 2 | 2016 |
| Chiltern International | For profit | 1 | 0 | 1 | 2016 |
2 organizations
Page 1 / 1